Improving the storage of immune cells for cancer treatment
Official title: Innovation of Biobanking for Cellular Adoptive Immunotherapies Based on a First-in-Class Biocompatible Cryopreservation Technology for T and NK Cells and Their CAR-Engineered Products
Funded at Cryocrate, LLC · NIH-10705271 · Data updated 2026-11-12
This study is testing a new way to safely freeze immune cells used in cancer treatments, which could make it easier for patients to get effective therapies without harmful substances.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cryocrate, LLC NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | September 15, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $864,173 |
| NIH project number | 5R44CA278579-02 |
| Project ID | NIH-10705271 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing or considering adoptive immunotherapy for cancer, particularly those with leukemia or other malignancies.
✕Less likely to help
Patients who are not candidates for immunotherapy or those with conditions that do not involve T or NK cell therapies may not benefit from this research.
What this research studies
This research focuses on developing a new cryopreservation technology called OdinSol® that allows for the safe and effective storage of immune cells, such as T and NK cells, which are crucial for adoptive immunotherapies in cancer treatment. The approach eliminates the need for toxic cryoprotectants and human serum, making the process safer and more efficient. By collaborating with various organizations, the team aims to ensure that this technology meets regulatory standards and demonstrates superior performance in preserving cell viability and functionality. Patients may benefit from improved access to effective immunotherapy treatments as a result of this innovation.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer immunotherapy treatments for cancer patients.
How similar studies have gone: Previous research has shown promise in improving cryopreservation techniques, but this specific approach using OdinSol® is novel and untested in clinical settings.
Where this research is happening
-
Cryocrate, LLC
Columbia, United States Active
Researchers
- Principal investigator: Han, Xu — Cryocrate, LLC
- Study coordinator: Han, Xu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.